• Home
  • About
  • All Companies
    • Recent
    • Summary Lists
  • Contact

Wild Biotech

  • April 16, 2021
  • New Biotech Startups

Israel-based Wild Biotech is mining wild animal microbiomes for the discovery of novel human therapeutics, based on the “largest database ever assembled of the microbiome of wild animals”.

Based on work published in Science, the company’s founders have sampled the faeces of 184 wild animals, including fish, birds, and mammals, from four different continents to discover more than 1,000 previously undescribed bacterial species and identified factors that correlate with the composition, diversity, and functional content of the microbiota. The company will continue to build the database.

The rationale for investigating wild animals is that they live in a much more hostile environment compared to humans, so will have had to develop more diverse solutions than the human microbiome to fight extreme conditions. As an example, some wild animals can safely eat rotting meat. The company’s database includes previously undescribed enzymes in the microbiomes of carrion eaters, which have been made in the lab and found to degrade a range of microbial toxins. It may be that in host animals the enzymes make rotten meat safe for consumption.

The potential landscape of therapeutic technologies for human diseases is wide, although the company intends to initially focus on inflammatory, immune and gastrointestinal diseases, and is at the preclinical stage with several lead compounds.


Subscribe for alerts on new companies featured on Startups.Bio


May 24, 2022Aulos Bioscience
Aulos Bioscience aims to revolutionize cancer patient care through the development of pioneering Interleukin-2 therapeutics for the treatment of solid tumor cancers. Interleukin-2 or IL-2 …
May 18, 2022Code Bio
Code Bio is using its novel targeted non-viral delivery platform to develop genetic medicines for serious and life-threatening diseases such as Type 1 Diabetes and …
May 9, 2022Muna Therapeutics
Muna Therapeutics aims to preserve brain function and enhance resilience to neurodegenerative diseases.  The company engages in the discovery and development of novel therapies that …
April 27, 2022Glyphic Biotechnologies
Glyphic Biotechnologies is an MIT spin-out aiming to accelerate the critical but slow step of sequencing new proteins, potentially cutting drug development times down by …
April 24, 2022ImmuneID 
ImmuneID is a precision immunology company that has developed a genome-wide, high-throughput platform to provide an understanding of individual immune responses. ImmuneID's aiSPIRE platform screens billions of …
April 15, 2022Flare Therapeutics
Flare uses a “switch-site based drug discovery approach” to develop a pipeline of therapeutic programs that target pivotal cancer drivers such as transcription factor dysregulation …

Tags:

© Copyright 2022. Startups.Bio, powered by VentureRadar.